Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi PharmaTech Acquires Genomics Company NextCODE for $65 Million

publication date: Jan 9, 2015
WuXi PharmaTech, the China-US CRO/CMO, paid $65 million in cash to acquire NextCODE Health, a genomic analysis and bioinformatics company with operations in the US and Iceland. One year ago, NextCODE was spun out of deCODE Genetics with a five-year exclusive license to deCODE's sequence-based clinical diagnostic applications. After the acquisition, WuXi will be involved in the clinical diagnostic market for the first time. The company says the transaction lays the groundwork for the creation of an integrated global enterprise for applying genomics to medicine. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital